This efficacy is relatively greater than that reported in the CP-MGAH22-05 study, which evaluated margetuximab plus pembrolizumab in pretreated HER2-positive GC.31 For the 2nd-line treatment of HER2-positive GC, the options for further anti-HER2 therapies were limited until several anti-HER2 ADCs developed. This evidence concerns the gene ERBB2 and gastric cancer.